News
NLSPW
0.0179
0.00%
0.00
Weekly Report: what happened at NCEL last week (0330-0403)?
Weekly Report · 1d ago
NewcelX Raises $1.35 Million in Premium-Priced Private Placement to Advance Type 1 Diabetes Program
TipRanks · 5d ago
BUZZ-U.S. STOCKS ON THE MOVE-Intel, Tempus AI, Boeing
Reuters · 6d ago
BUZZ-U.S. STOCKS ON THE MOVE-Cal-Maine, Rivian, Alkermes
Reuters · 6d ago
NewcelX prices $1.35M equity financing
Seeking Alpha · 6d ago
BUZZ-NewcelX rises after raising funds at premium to boost diabetes program
Reuters · 6d ago
NewcelX Enters Securities Purchase Agreements For Private Placement At $2.75 Per Share, 30% Premium To Last Close
Benzinga · 6d ago
NewcelX prices $1.35 million private placement at 30% premium to market
Reuters · 6d ago
NewcelX Announces Pricing of $1.35 Million Equity Financing at 30% Premium Pricing
Barchart · 6d ago
Weekly Report: what happened at NCEL last week (0323-0327)?
Weekly Report · 03/30 10:08
Weekly Report: what happened at NCEL last week (0316-0320)?
Weekly Report · 03/23 10:04
NewcelX AG files Form 3 for Chairman and CEO Ronen Twito
Reuters · 03/18 11:07
NewcelX AG Director Samuel Olivier Files Initial Beneficial Ownership Statement
Reuters · 03/18 11:02
NewcelX AG director Iohan Eran Israel files initial beneficial ownership statement
Reuters · 03/18 10:55
NewcelX AG director Alexander Zwyer files initial beneficial ownership statement
Reuters · 03/18 10:44
Weekly Report: what happened at NCEL last week (0309-0313)?
Weekly Report · 03/16 10:04
NewcelX Forms Eledon Alliance to Accelerate NCEL-101 Diabetes Program
TipRanks · 03/09 11:47
NewcelX announces research agreement with Eledon Pharmaceuticals
TipRanks · 03/09 11:12
NEWCELX AG - COLLABORATION TO INTEGRATE NCEL-101 WITH ELEDON'S TEGOPRUBART (AT-1501)
Reuters · 03/09 11:00
NEWCELX ANNOUNCES STRATEGIC COLLABORATION WITH ELEDON PHARMACEUTICALS TO ADVANCE NCEL-101 PROGRAM FOR TYPE 1 DIABETES
Reuters · 03/09 11:00
More
Webull provides a variety of real-time NLSPW stock news. You can receive the latest news about NEWCELX LTD through multiple platforms. This information may help you make smarter investment decisions.
About NLSPW
NLS Pharmaceutics AG, formerly NLS 1 Pharma AG, is a Switzerland-based company that operates as a biopharmaceutical company. The Company focuses on development of medicines for neurobehavioral and neurocognitive disorders treatment. The Company serves customers worldwide.